Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Gain Therapeutics Inc (GANX) USD0.0001

Sell:$7.10 Buy:$7.43 Change: $0.02 (0.27%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Sell:$7.10
Buy:$7.43
Change: $0.02 (0.27%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Sell:$7.10
Buy:$7.43
Change: $0.02 (0.27%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Gain Therapeutics, Inc. is a holding company. The Company, through its subsidiary, GT Gain Therapeutics SA, is a development stage biotechnology company. The Company is focused on developing therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. It uses its platform, Site-Directed Enzyme Enhancement Therapy (SEE-Tx), to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treating the underlying disease. Its pipeline includes its Structurally Targeted Allosteric Regulators (STARs), which are small molecules with the potential to treat diseases with unmet medical need. These diseases include Morquio B, GM1 Gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s disease, Krabbe disease and Mucopolysaccharidosis type 1.

Contact details

Address:
4800 Hampden Lane, Suite 200
BETHESDA
20814
United States
Telephone:
+1 (301) 5001556
Website:
https://www.gaintherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GANX
ISIN:
US36269B1052
Market cap:
$91.35 million
Shares in issue:
11.88 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.